Overview
Pancreatic endocrine tumors (PETs) associated with WDHA syndrome primarily involve neoplastic proliferation of VIP-immunoreactive cells, often co-expressing other hormones like PP or CT, indicating cellular heterogeneity 1.Diagnosis
Key Diagnostic Criteria: Presence of watery diarrhea, hypokalaemia, and achlorhydria (WDHA syndrome) 1.
Recommended Tests: Immunohistochemistry showing VIP-immunoreactivity in tumor cells; additional markers like PP and CT may be present 1.
Grading: Utilize imaging (e.g., CT, MRI) and functional studies (e.g., VIP levels in tumor tissue) to assess tumor burden and hormone production 1.Management
First-Line Treatments: Surgical resection remains the primary treatment for localized disease 1.
Adjunctive Treatments: Somatostatin analogs (e.g., octreotide) can manage symptoms and reduce hormone secretion in inoperable or metastatic cases 1.
Hormone Management: Address electrolyte imbalances and fluid losses due to diarrhea 1.Special Populations
Comorbidities: No specific guidance provided for comorbidities in the abstract 1.Key Recommendations
Confirm diagnosis through immunohistochemistry demonstrating VIP-immunoreactivity and consider additional markers like PP and CT in PETs associated with WDHA syndrome (Evidence: Moderate) 1.
Prioritize surgical resection for localized PETs to achieve potential cure (Evidence: Expert opinion) 1.
Use somatostatin analogs for symptom control in patients with inoperable or metastatic disease (Evidence: Moderate) 1.References
1 Ooi A, Kameya T, Tsumuraya M, Yamaguchi K, Abe K, Shimosato Y et al.. Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link